Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CPRX Catalyst Pharmaceuticals	$20.38 +0.9%	$21.06	$19.00 ▼ $26.58	$2.47B	0.7	1.50 million shs	1.09 million shs
GMTX Gemini Therapeutics	$59.95 +0.3%	$57.21	$1.16 ▼ $14.10	$2.60B	-0.12	189,291 shs	165,212 shs
IMTX Immatics	$5.28 -2.2%	$5.96	$3.30 ▼ $13.09	$656.37M	0.93	639,308 shs	324,860 shs
IMVT Immunovant	$14.82 -2.4%	$16.35	$12.72 ▼ $34.47	$2.65B	0.66	1.18 million shs	662,669 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CPRX Catalyst Pharmaceuticals	+1.25%	-0.74%	-2.93%	-17.86%	-1.37%
GMTX Gemini Therapeutics	+0.63%	+2.76%	-1.36%	+32.50%	+20.22%
IMTX Immatics	+0.93%	-3.57%	-19.04%	-0.74%	-50.59%
IMVT Immunovant	+0.66%	+2.43%	-9.43%	+1.95%	-52.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CPRX Catalyst Pharmaceuticals	4.8983 of 5 stars	3.6	1.0	0.0	3.9	3.4	3.3	3.8
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	2.1523 of 5 stars	3.4	3.0	0.0	0.0	2.0	1.7	0.0
IMVT Immunovant	3.0266 of 5 stars	4.4	2.0	0.0	0.0	3.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CPRX Catalyst Pharmaceuticals	3.13	Buy	$33.20	62.90% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
IMTX Immatics	2.83	Moderate Buy	$14.67	177.78% Upside
IMVT Immunovant	2.83	Moderate Buy	$35.20	137.52% Upside

Current Analyst Ratings Breakdown

Latest IMTX, IMVT, GMTX, and CPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	CPRX Catalyst Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/15/2025	IMTX Immatics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/12/2025	IMVT Immunovant	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $37.00
8/12/2025	IMVT Immunovant	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$33.00 ➝ $30.00
8/11/2025	IMVT Immunovant	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/28/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$17.00 ➝ $18.00
7/10/2025	IMVT Immunovant	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$18.00
6/5/2025	CPRX Catalyst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/28/2025	IMTX Immatics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CPRX Catalyst Pharmaceuticals	$491.73M	5.07	$2.47 per share	8.25	$6.99 per share	2.92
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
IMTX Immatics	$168.65M	3.81	$0.24 per share	22.10	$4.34 per share	1.22
IMVT Immunovant	N/A	N/A	N/A	N/A	$3.49 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CPRX Catalyst Pharmaceuticals	$163.89M	$1.65	12.35	9.57	0.82	37.36%	40.78%	35.36%	11/5/2025 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
IMTX Immatics	$16.47M	-$0.65	0.00	N/A	N/A	-59.29%	-15.60%	-12.31%	N/A
IMVT Immunovant	-$413.84M	-$2.85	0.00	N/A	N/A	N/A	-80.99%	-72.23%	11/6/2025 (Estimated)

Latest IMTX, IMVT, GMTX, and CPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q1 2025	IMTX Immatics	-$0.38	-$0.66	-$0.28	-$0.66	$13.05 million	$6.48 million
8/11/2025	Q1 2026	IMVT Immunovant	-$0.69	-$0.60	+$0.09	-$0.71	N/A	N/A
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CPRX Catalyst Pharmaceuticals	N/A	6.71	6.55
GMTX Gemini Therapeutics	N/A	71.49	71.49
IMTX Immatics	N/A	8.80	8.80
IMVT Immunovant	N/A	12.32	12.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CPRX Catalyst Pharmaceuticals	79.22%
GMTX Gemini Therapeutics	75.42%
IMTX Immatics	64.41%
IMVT Immunovant	47.08%

Insider Ownership

Company	Insider Ownership
CPRX Catalyst Pharmaceuticals	10.40%
GMTX Gemini Therapeutics	12.90%
IMTX Immatics	3.30%
IMVT Immunovant	1.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CPRX Catalyst Pharmaceuticals	80	122.39 million	109.66 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
IMTX Immatics	260	121.55 million	117.54 million	Optionable
IMVT Immunovant	120	174.32 million	171.18 million	Optionable

IMTX, IMVT, GMTX, and CPRX Headlines

Recent News About These Companies

Immunovant Stockholders Approve Key Governance Decisions

5 hours ago | tipranks.com

Immunovant, Inc. $IMVT Shares Purchased by Affinity Asset Advisors LLC

August 28 at 9:02 AM | marketbeat.com

Jump Financial LLC Raises Stock Holdings in Immunovant, Inc. $IMVT

August 28 at 6:15 AM | marketbeat.com

Immunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of "Moderate Buy" from Analysts

August 28 at 3:25 AM | marketbeat.com

IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm

August 27 at 8:33 PM | businesswire.com

Charles Schwab Investment Management Inc. Grows Position in Immunovant, Inc. $IMVT

August 26 at 3:21 AM | marketbeat.com

Swiss National Bank Acquires 30,800 Shares of Immunovant, Inc. $IMVT

August 25 at 3:29 AM | marketbeat.com

T. Rowe Price Investment Management Inc. Increases Holdings in Immunovant, Inc. $IMVT

August 24, 2025 | marketbeat.com

Vanguard Group Inc. Raises Stock Holdings in Immunovant, Inc. $IMVT

August 24, 2025 | marketbeat.com

Aberdeen Group plc Increases Stock Position in Immunovant, Inc. $IMVT

August 21, 2025 | marketbeat.com

Deutsche Bank AG Raises Stake in Immunovant, Inc. (NASDAQ:IMVT)

August 18, 2025 | marketbeat.com

Tejara Capital Ltd Makes New Investment in Immunovant, Inc. (NASDAQ:IMVT)

August 17, 2025 | marketbeat.com

Q2 Earnings Estimate for Immunovant Issued By HC Wainwright

August 16, 2025 | marketbeat.com

Q2 EPS Estimates for Immunovant Decreased by Leerink Partnrs

August 16, 2025 | marketbeat.com

Lifesci Capital Predicts Immunovant Q2 Earnings

August 16, 2025 | marketbeat.com

Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack

August 15, 2025 | seekingalpha.com

Connor Clark & Lunn Investment Management Ltd. Purchases 128,345 Shares of Immunovant, Inc. (NASDAQ:IMVT)

August 14, 2025 | marketbeat.com

JPMorgan Chase & Co. Lowers Immunovant (NASDAQ:IMVT) Price Target to $37.00

August 13, 2025 | marketbeat.com

Bank of America Issues Pessimistic Forecast for Immunovant (NASDAQ:IMVT) Stock Price

August 13, 2025 | marketbeat.com

Immunovant price target lowered to $30 from $33 at BofA

August 13, 2025 | msn.com

Immunovant (NASDAQ:IMVT) Trading Down 6.3% - Should You Sell?

August 12, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX, IMVT, GMTX, and CPRX Company Descriptions

Catalyst Pharmaceuticals NASDAQ:CPRX

$20.38 +0.19 (+0.94%)

Closing price 04:00 PM Eastern

Extended Trading

$20.60 +0.22 (+1.05%)

As of 07:36 PM Eastern

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Gemini Therapeutics NASDAQ:GMTX

$59.95 +0.17 (+0.28%)

As of 08/27/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Immatics NASDAQ:IMTX

$5.28 -0.12 (-2.22%)

Closing price 04:00 PM Eastern

Extended Trading

$5.27 -0.01 (-0.19%)

As of 05:10 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Immunovant NASDAQ:IMVT

$14.82 -0.36 (-2.37%)

Closing price 04:00 PM Eastern

Extended Trading

$15.00 +0.19 (+1.25%)

As of 07:30 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time